Monitoring early clearance of circulating tumor DNA as an effective tool to predict clinical benefits of immune checkpoint inhibitors in lung cancer patients: The preliminary results from clinical trial NCT04203095.

Di Zheng,Jian Ni,Yi Zhong,Qian Ziliang,Baiyun Wang

Monitoring early clearance of circulating tumor DNA as an effective tool to predict clinical benefits of immune checkpoint inhibitors in lung cancer patients: The preliminary results from clinical trial NCT04203095.

2020

Di Zheng
Jian Ni
Yi Zhong
Qian Ziliang
Baiyun Wang

e15056Background: Immuno-checkpoint inhibitors (ICI)is the stand-of-care of lung cancer treatment nowadays. But it’s still challenging to find an effective biomarker to predict clinical benefits fr...

Keywords:

Oncology
Lung cancer
Circulating tumor DNA
Clinical trial
immune checkpoint inhibitors
Pathology
Medicine
Internal medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations